Navigation Links
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Date:2/7/2013

WORCESTER, Mass. and TORONTO, Feb. 7, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today provided an overview of the current pipeline and potential of its wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com). While the Company is currently in a late Phase IIb trial of a very promising new immunotherapy for early breast cancer (AE37), the Company has made concrete headway in demonstrating a robust pipeline for AE37 indications beyond breast cancer, as well as for the technology behind it. Immediately behind its Phase III-ready breast cancer program, the Company has completed a Phase I prostate cancer trial and established a protocol for Phase II. While Herceptin targets the same tumor-associated protein as does AE37 therapy, Herceptin is not approved for breast cancer patients with low levels of HER2 expression, limiting Herceptin treatment to roughly 25% of breast cancer patients. Low levels of HER2 protein have been shown on several cancers, including men with prostate cancer. AE37 is being further researched in this larger population of patients whose tumors express only low levels of HER2.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)

While breast and prostate cancers are the initial indications being investigated for AE37, nearly all cancers of the gastrointestinal tract as well as lung, ovarian, bladder, and other cancers also express low levels of HER2. AE37 future research may help establish its role in many cancers in addition to breast and prostate cancer. A unique aspect of Antigen Express technology, which has enabled the promising results obtained so far from the AE37 Phase IIb trial in early breast cancer, is the Ii-Key technology
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)...   ViaDerma, Inc. (OTCQB: VDRM), a ... to market, has recently released a revolutionary new ... topical liquid tetracycline-based antibiotic that uses a patent-pending ... medication active ingredients into topical drugs. The drug ... to help prevent skin infection in minor cuts, ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues, today announced today ... be released on Thursday, November 6, 2014, and that ... webcast at 1:30 p.m. PST that afternoon. Management will ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Support Development,of Omega DUROS Continuous Delivery Therapy, ... Intarcia,Therapeutics, Inc., a privately held biopharmaceutical company,today ... study of omega,interferon with or without ribavirin ... C. The results demonstrate that,omega interferon in ...
... Conn., April 12, 2007 /PRNewswire-FirstCall/ --,CuraGen Corporation ... (PXD101), a histone deacetylase (HDAC) inhibitor being,investigated ... a protein,being investigated for the prevention of ... upcoming American Association for Cancer,Research (AACR) 2007 ...
Cached Medicine Technology:Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
(Date:10/31/2014)... Steven Reinberg HealthDay Reporter THURSDAY, ... increase slightly the risk of broken bones and injured joints, a ... found that among 7 percent of people who had an eczema ... joint injury and 0.6 percent had an injury that caused a ... with the skin condition had more than double the risk of ...
(Date:10/30/2014)... October 30, 2014—(BRONX, NY)—Investigators at Albert Einstein ... and Montefiore Medical Center will present their ... America,s (GSA) 67th Annual Scientific Meeting. Topics include ... survival, risk factors for cognitive impairment and the ... place November 5-9, 2014 in Washington, D.C., "Einstein-Montefiore ...
(Date:10/30/2014)... – You have to be at least 2 years ... younger babies, no official U.S. guidance exists other than ... mothers exclusively breastfeed for at least the first six ... , That,s the question that motivated researchers at ... Sciences to study the eating patterns of American infants ...
(Date:10/30/2014)... October 30, 2014 Nutrition Leaders, a ... weight loss aids, and more, is currently hosting a ... is already underway, is open to U.S. residents age ... December 15, 2014. One lucky winner will then be ... a $100 gift card to NutritionLeaders.com. , Nutrition Leaders’ ...
(Date:10/30/2014)... 30, 2014 Don Allred Insurance, a ... insurance plans for North Carolina residents, is excited to ... Burlington’s Holly Hill Mall. The new branch has been ... helping customers through all facets of the insurance selection ... Insurance spokesman Scott Allred couldn’t be happier with the ...
Breaking Medicine News(10 mins):Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2
... with Exciting New Line ... of Toys, ALPHARETTA, ... Bright Starts(TM) introduces its newest collection of,toys designed to delight babies with endless ... as he or,she explores a wide range of toys, from plush pals to ...
... ORANGE, N.J., July 8 The Henry H. ... people with,disabilities, announced today two key personnel changes ... A. DeLisa, M.D., current President of Kessler,Medical Rehabilitation ... while John DeLuca, Ph.D. will become the Vice ...
... Data, Structured Reporting, Scheduling and ... OAKLAND, Calif., July 8 The University of ... suite of IT,applications to equip their CV service lines ... to integrate disparate,systems, streamline workflow, improve quality, and help ...
... Improve Quality of Patient Data System, CAMBRIDGE, ... plc (LSE: AU. or AU.L), a global leader ... Servicio,Extremeno de Salud (SES), a provider of public ... Extremadura region of Spain, has selected,Autonomy,s Meaning-based Computing ...
... GRAS announces two new important features. A brand new version ... on-the-fly photometric analysis and report generation. The second item, is a ... imaging for themselves using the G13 telescope, located in Australia (more ... ...
... MedRetreat Offers 5 Steps to Help International Medical Providers Partner With Only ... ... 8, 2008 -- As interest in medical tourism heats up ... up to cash in on the emerging industry. But international hospitals should ...
Cached Medicine News:Health News:Bright Starts(TM) Adds New Twist to Old Favorites 2Health News:Bright Starts(TM) Adds New Twist to Old Favorites 3Health News:The Henry H. Kessler Foundation Appoints New Vice President for Research and Strengthens Relationship With Current Research Luminary 2Health News:Building a Fully Integrated Cardiovascular Imaging and Information System Webinar 2Health News:Spanish Health Service Provider Selects Autonomy to Deliver Innovation Within Healthcare 2Health News:Spanish Health Service Provider Selects Autonomy to Deliver Innovation Within Healthcare 3Health News:GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems 2Health News:GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems 3Health News:An American Appeal to Overseas Hospitals 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: